Immunovant Set to Release Q3 2026 Earnings on February 6

Immunovant (NASDAQ: IMVT) is scheduled to announce its financial results for the third quarter of fiscal year 2026 on February 6, 2026, prior to the market opening. Analysts anticipate that the company will report earnings of ($0.71) per share for this quarter. Investors and analysts can access details on the earnings call, which is set for 8:00 AM ET on the same day, through the company’s official earnings results page.

The company’s previous quarterly earnings report was released on November 10, 2025. During that period, Immunovant reported an earnings per share (EPS) of ($0.73), falling short of analysts’ expectations of ($0.72) by ($0.01). In the corresponding quarter of the previous year, the firm recorded an EPS of ($0.74). Looking ahead, analysts project that Immunovant will report an EPS of ($3.00) for both the current and next fiscal years.

Market Performance and Insider Activity

On February 5, 2026, shares of Immunovant opened at $25.15, marking a 2.5% decline in trading. The company currently holds a market capitalization of $4.41 billion, with a price-to-earnings ratio of -8.86. The stock has experienced a fifty-day simple moving average of $25.55 and a two-hundred-day average of $20.66. Over the past year, the share price has fluctuated between a low of $12.72 and a high of $27.80.

Recent insider transactions have raised eyebrows, with Tuyl Christopher Van, an insider, selling 10,813 shares on December 18, 2025, at an average price of $26.91, totaling $290,977.83. Following this sale, Van now holds 149,930 shares, valued at approximately $4,034,616.30. This transaction represents a 6.73% reduction in his stake in the company. Additionally, Director Andrew J. Fromkin sold 22,249 shares at an average price of $23.25 on December 1, 2025, amounting to $517,289.25. After this sale, Fromkin’s remaining shares total 85,852, valued at around $1,996,059. In total, insiders have sold 63,868 shares valued at $1,538,470 in the last 90 days, with insiders owning 1.80% of the company’s stock.

Institutional Investment Trends

Recent trading activity among institutional investors indicates a mixed interest in Immunovant. Prelude Capital Management LLC acquired a new position in the firm valued at approximately $672,000 during the third quarter. Similarly, Algert Global LLC also purchased new shares worth $563,000. Creative Planning increased its holdings by 8.9%, now owning 38,503 shares valued at $621,000 after acquiring an additional 3,135 shares.

Other notable movements include LMR Partners LLP, which acquired a new stake valued at $401,000, and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., which increased its position by 4.1% during the second quarter. Currently, hedge funds and institutional investors control 47.08% of the company’s stock.

Immunovant is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies targeting the neonatal Fc receptor (FcRn). This approach aims to address severe autoimmune diseases by inhibiting FcRn to reduce the levels of pathogenic immunoglobulin G (IgG) antibodies. The company’s lead product, efgartigimod, is designed to selectively bind to FcRn, thereby accelerating the degradation of circulating IgG.

As Immunovant prepares for its earnings announcement, stakeholders will be watching closely to gauge the company’s financial health and strategic direction amid evolving market conditions.